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PREFACE
The main body of this thesis in Chapter III is a journal article entitled “A degradable
chitosan derivative based delivery system for local delivery of antimicrobials: Preliminary
Evaluations and Assessments” This manuscript was submitted to the Journal of Biomedical
Materials Research Part B: Applied Biomaterials.
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ABSTRACT
Complex musculoskeletal wounds with high rates of infection can be managed with local
delivery systems and systemic antimicrobials. Chitosan has been shown to be biocompatible and
biodegradable but exhibits bolus release kinetics. Trimethyl chitosan (TMC) has tailorable
degradation properties, and poly(ethylene glycol) diacrylate chitosan (PEGDAc) is cross-linked
and exhibits enhanced swelling characteristics. This research investigated a combination of TMC
and PEGDAc as an injectable local delivery system. Combination paste eluted active
vancomycin and amikacin for 6 and 5 days, respectively, and was degraded after 14 days.
Cytocompatibility with NIH3T3 fibroblast and MC3T3 pre-osteoblast cells was above viability
standards in ISO 10993-5. Combination paste required 12% of a benchmark force to eject from
standard 1 mL syringes. The combination adhered to muscle tissue and was easily removed by
irrigation. These preliminary results indicate the combination of TMC and PEGDAc could be
further developed for infection prevention.
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CHAPTER I
INTRODUCTION
Statement of Clinical Problem
Bacterial infections are one of the most dreaded complications for any classification of
injury or surgical procedure. Injuries sustained from high-energy trauma such as car accidents,
sports injuries, or explosive blasts are particularly prone to bacterial colonization.1,2 These
classes of injury typically involve a combination of soft and hard tissue with complex geometries
and compromised vasculature that is ideal for bacterial adherence and growth. Administration of
systemic antibiotics within 3 hours of sustaining injury has been associated with decreased
infection rates.3,4 If antibiotics are not administered during this time frame or are not effective
against the invading pathogen, infection may develop and substantially increase morbidity,
mortality, and difficulty of treating the injury. A recent study investigated the incidence of
casualties during the wars in Iraq and Afghanistan and found that 77% of all casualties sustained
a musculoskeletal wound.1 Another study showed infection of severe Type III tibial fractures in
the U.S. military population led to a significant decrease in the rate of soldiers returning to active
duty (24% vs. 44%) compared to uninfected fractures.5 In the civilian population,
musculoskeletal trauma accounts for more than 50% of the total costs on society for nonfatal
injuries, and 42% of civilians subjected to high-energy trauma do not return to work 1 year after
their injury.4 Treatment of infected high-energy extremity wounds that affect soft and hard
tissues usually requires external fixation and systemic antimicrobials with an adjunctive local
antimicrobial delivery system included. Another significant source of bacterial infections is
hospital acquired infections, also known as nosocomial infections. The Centers for Disease
Control and Prevention published a study that estimated there were nearly 722,000 hospital
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acquired infection in 2011.6 This study reported that surgical site infections are responsible for
21.8% of hospital acquired infections and another 25.6% are due to device-associated infections.
Bacteria acquired in hospitals are potentially more resistant to antimicrobials and difficult to treat
compared to bacteria found outside of hospitals.7 Preoperative prophylaxis with systemic
antibiotics is the most common method for preventing surgical site infections or deviceassociated infections.8 However, if systemic antibiotics fail to prevent the infection, treatment of
the resulting infection may include an adjunctive local antimicrobial delivery system.9
Currently available treatments for these severe infections depends on the type of injury
sustained. For injuries that encompass soft and hard tissues, poly(methyl methacrylate) (PMMA)
beads and calcium sulfate pellets are common choices.10 Superficial injuries that only engage
soft tissue can potentially be treated using a range of delivery systems made from materials such
as collagen, poly(lactic acid) (PLA), poly(glycolic acid) (PGA), or other polymers. Collagen,
PLA, and PGA have been approved by the FDA for a number of biomedical applications, but
collagen has been used the most of these materials for soft tissue injures.11 Each of these systems
possesses advantages that make them useful, but they also possess disadvantages that limit their
application in musculoskeletal trauma. PMMA has excellent mechanical properties and spacefilling capacity, but it does not degrade in the body and necessitates a secondary surgery for
removal.10 Calcium sulfate is a resorbable, osteoconductive material that degrades in a similar
time frame as bone formation. However, rapid degradation to calcium ions may cause serous
wound drainage in up to 51% of cases.10,12 Collagen based systems are completely degraded by
the body and releases the majority of its therapeutic load, but they are expensive and have
weaker mechanical properties compared to synthetic systems.13 PLA and PGA systems can be
tailored to control their release kinetics, degradation properties, and mechanical properties, but
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they degrade to acidic waste products that may incite inflammatory responses, and the acidic
degradation products accelerate the degradation of the bulk system.13 Initial management of
complex musculoskeletal trauma could be improved by developing a delivery system that is
injectable to enhance wound coverage, adhesive to minimize migration from the wound site,
degradable in the same time frame as elution kinetics to eliminate removal, and biocompatible to
not adversely affect the surrounding tissue.
Chitosan is the second most abundant biopolymer found in nature and has been
developed into a multitude of delivery systems.14,15 Chitosan based delivery systems have been
shown to be biocompatible, biodegradable, and compatible with a wide range of therapeutics.15
However, these systems experience bolus release kinetics, and it would improve infection
prevention capabilities if therapeutic release was extended.10 Chitosan derivatives are chemically
modified derivatives of chitosan that impart improved properties to chitosan without sacrificing
the inherent biocompatibility and biodegradability.16 Selected enhanced characteristics that could
improve local therapeutic delivery properties include increased swelling ratio, solubility at
neutral pH, and range of compatible therapeutics.17 Trimethyl chitosan has been shown to have
enhanced solubility at neutral pH and be able to degrade at the same rate or faster than
unmodified chitosan.18 Poly(ethylene glycol) diacrylate chitosan has been investigated as an
adhesive delivery system, and the cross-linked structure provides an enhanced swelling ratio.19
Chitosan pastes have previously been developed as an injectable delivery system for
complex musculoskeletal trauma. The first generation of this system combined acidic and
neutralized chitosan components, and the resulting system was able to elute antimicrobials for 3
days, injectable, adhesive, and enzymatically degradable. However, there were issues with in
vivo biocompatibility, and future developments were designed to improve biocompatibility. The
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following iteration reduced the amount of acidic component and added poly(ethylene glycol) to
the neutral component.20 These modifications ameliorated the biocompatibility issues but
resulted in a loss of its advantageous degradation and adhesion characteristics. Attempting to
retain the biocompatibility and regain the lost characteristics, the composition of chitosan paste
was further modified by reducing the acid content of the acidic component and removing the
neutral component.21 This system experienced a mismatch between elution and degradation by
being enzymatically degraded in two days and eluting antimicrobials for 3 days. Combining the
mismatch between elution and degradation with a lack of adhesivity, chitosan paste requires
further improvement.
Hypothesis and Research Objectives
TMC and PEGDAc were synthesized to assess feasibility as a local delivery system for
preventing infection in extremity injury patients with complex musculoskeletal trauma. It was
hypothesized that a combination of TMC and PEGDAc would have extended elution and
extended degradation compared to non-derivatized paste. Research objectives were to extend
elution of antimicrobial agents compared to previously developed systems with a target between
3 and 7 days. Elution for 7 days would provide protection from bacteria during initial wound
closure and dressing changes. Another goal is to have complete degradation of the system
between 7 and 14 days to allow for initial healing of soft tissue. The final objective is to enhance
the adhesive characteristics compared to previously developed systems. Preventing migration of
the delivery system from the wound site is crucial for maintaining high concentrations of
antimicrobial at the wound site. TMC will allow degradation rate to be tailored by varying the
degree of quaternization, and this will provide a mechanism for matching degradation properties
and elution kinetics of the local delivery system. Inclusion of PEGDAc will enhance swelling
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characteristics and adhesiveness of the material; these additional properties will allow
incorporation of more aqueous antimicrobial solution and better adhesion to open wounds.
Secondary objectives include maintaining cytocompatibility with representative cell lines,
injectability for easy application, and point-of-care loading for increased treatment options.
Specific research objectives are the following:
1. Determine if the elution kinetics of active vancomycin and amikacin from a combination
of TMC and PEGDAc are extended compared to previously developed systems and
maintained between 3 and 7 days.
2. Determine if the enzymatic degradation rate of the combination of TMC and PEGDAc
can be tailored to last between 7 and 14 days.
3. Determine if the combination of TMC and PEGDAc is cytocompatible according to ISO
10993-5 with cells lines representative of tissues present in open fractures.
4. Determine if the combination of TMC and PEGDAc is more adhesive compared to
previously developed systems.
5.

Determine if the combination of TMC and PEGDAc is considered injectable through
standard 1 mL syringes according to benchmark force values.
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CHAPTER II
LITERATURE REVIEW
Musculoskeletal Trauma
Trauma associated with the musculoskeletal system poses a significant burden on
healthcare systems around the globe. In developed countries, this classification of injury is the
leading cause of death in patients that are younger than 44 years old.4 Musculoskeletal trauma
caused by high-energy injuries such as car accidents, gun shots, sports injuries, or explosive
blasts may result in an open fracture. Court-Brown et al. performed a 15 year retrospective study
on open fractures treated at their hospital and reported an incidence rate of 30.7 fractures per
100,000 people per year.22 Using this figure, approximately 100,000 of these traumatic injuries
occur each year in the United States. However, this estimate only encompasses the incidence rate
for the civilian population and does not take military personnel into account. Belmont et al.
retrospectively reviewed all of the musculoskeletal injuries incurred during the conflicts in Iraq
and Afghanistan and found the incidence of open fractures to be 1.27 injuries per 1,000 deployed
military personnel per year.1
The presence of environmental contaminants, complex geometries, and compromised
vasculature make management of open fractures difficult. Initial treatment is to administer
systemic antimicrobials as quickly as possible after sustaining the injury to prevent infection.
Current clinical guidelines established by both civilian and military trauma surgeons agree that
antimicrobials should be administered within 3 hours of injury, and it is an independent risk
factor for infection if administered outside of this window.3,23 To enhance the efficacy of
infection prevention, a local delivery system may be placed at the wound site to deliver
antimicrobials directly to the site of injury.10 The next step of management includes irrigation
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and debridement of the wound to remove any superficial contaminants or nonviable tissues
followed by the placement of a fixation device. Orthopaedic fixation devices facilitate
ambulation, promote healing, and prevent further soft tissue injury and may include external
fixation, intramedullary nailing, or a combination of plates and screws.23 Closure of the wound is
the final step in managing these traumatic injuries, and delay of this procedure predisposes
patients to acquiring nosocomial infections. Despite these established treatment protocols,
patients with open fractures remain susceptible to serious complications such as infection,
nonunion, malunion, and wound necrosis.24
Infection rates for the most severe classification of open fractures can be as high as 50%
and result in an elevated risk of complications, duration of hospitalization, number of
readmissions, and twice the costs compared to uninfected patients.25-27 The same factors that
make treatment of open fractures difficult also make them prone to infection. Damaged
vasculature prevents injured tissues from being perfused by the innate immune system and
systemic antimicrobials. Contamination of the wound site places bacteria in close proximity to
necrotic soft tissue and devascularized bone. Also, the complex geometries of these injuries
hinders the efficacy of irrigation and debridement by providing bacteria with crevices to adhere
and provide protection. Necrotic tissues and fixation devices serve as ideal substrates for bacteria
to adhere and form a biofilm.28 The most common pathogens associated with orthopaedic
infections belong to the Staphylococcus genus, accounting for nearly 67% of infections.29
Pseudomonas aeruginosa (P. aeruginosa) has also been found contaminating open fractures, and
the combination of these species accounts for nearly 75% of biofilm-based medical device
infections.30 Biofilms are difficult to treat due to several factors including the extracellular
polysaccharide matrix, persister cells, horizontal gene transfer, and limited diffusion.28
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Antimicrobials concentrations required to eradicate these infections can be as high as 1000x the
amount required to eliminate planktonic bacteria.31 These concentrations are impossible to
deliver through the systemic vasculature without eliciting adverse effects from the chosen
antimicrobials even if the vasculature was not damaged. Therefore, it is imperative to prevent
these infections from occurring.
Hospital Acquired Infections
Nosocomial infections, otherwise known as hospital acquired infections, are dreaded
complications that affect vulnerable patients while they are receiving treatment within a
healthcare facility. The Centers for Disease Control and Prevention published a report that
estimated 722,000 of these infections occurred in the United States in 2011.6 Among these
infections, surgical site infections and device associated infections are the most common with
incidences of 30% and 25.6%, respectively.6,8 Device associated infections encompass all
medical devices, but the focus here is on devices with an orthopaedic application. Common sites
for orthopaedic infections are implanted fracture fixation devices and prosthetic devices used in
the management of hip or knee osteoarthritis .While periprosthetic joint infection only occurs in
1% of total hip arthroplasties (THA) and 2% of total knee arthroplasties (TKA), they account for
14.8% and 25.2% of failures, respectively.32 The volume of THAs and TKAs is projected to
grow to 572,000 and 3,480,000 procedures by 2030 in the United States, and the cost of revision
surgeries will pose a significant burden on the U.S. healthcare system. Patients that acquire one
of these infections will experience an increased length of stay, number of readmissions, risk of
complications, and cost of treatment.27,33
Patients diagnosed with periprosthetic joint infection can be managed by surgical or
nonsurgical treatment methods.34 Infections caused by low virulence bacteria that are susceptible
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to antimicrobials may be treated using systemic antimicrobials and debridement with component
retention.35 However, if the infection is caused by a virulent or antimicrobial resistant bacteria,
patients are most often treated using a two-stage revision in the United States.34 In a two-stage
revision, the prosthetic components and bone cement are removed, and a PMMA spacer
impregnated with antimicrobials is used to manage the dead space and combined with systemic
antimicrobials to eliminate the invading pathogens. The overall cost of this treatment ranges
from $60,000 to $100,000 and must be repeated if the infection resurges.36
Management of patients with surgical site infections is less invasive and costly compared
to patients with periprosthetic joint infection. Superficial infections may only require wound
drainage to be effective; whereas, deep infections require managing the site of infection and
administering antimicrobials.8 Treatment of these infections may range from $400 to $30,000
depending on the severity of infection.11 Infection treatment does not only affect the cost to
patients but also substantially increases the costs for healthcare systems.
Prevention of hospital acquired infections is fundamentally different from preventing
infections of open fractures. The factors that complicate infection prevention in fractures are not
present at surgical sites. These injuries have an adequate blood supply, well defined geometries,
and a lack of environmental contaminants.34 Also, patients at risk for developing an infection are
prophylactically administered antimicrobials prior to operation.11 Theoretically, this measure
would reduce the incidence of surgical site infections to 0%, but this is not the case. There are
several reasons why this occurs: non-adherence to antimicrobial regimen, inappropriate
antimicrobial selection, and antimicrobial-resistant pathogens. The most common pathogens that
affect these wounds are Staphylococcus aureus (S. aureus), Staphylococcus epidermis (S.
epidermis), and P. aeruginosa. There have been many reports of antimicrobial resistance
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developing in these microorganisms such as methicillin-resistant S. aureus (MRSA),
vancomycin-resistant S. aureus (VRSA), and multi-drug resistant P. aeruginosa.30,37,38
Resistance can be acquired through many different mechanisms such as inactivation of the
antimicrobial, destruction of the antimicrobial, decreased permeability of the bacterial cell
membrane, increased efflux of the antimicrobial, and modifications of the target site.39 Excluding
modification of the target site, the other resistance mechanisms are mediated through enzymatic
processes which can be saturated at large concentrations of antimicrobials. However, the
concentrations required to overcome these mechanisms cannot be achieved through systemic
delivery without producing adverse effects.
Local Therapeutic Delivery
Systemic delivery of antimicrobials is an effective treatment for preventing most
infections, but it is ineffective for injuries with compromised vasculature, antimicrobial resistant
pathogens, or biofilm-based infections. Shortcomings of systemic delivery may be minimized by
incorporating local delivery systems as adjunctive therapies. Local delivery systems are capable
of achieving concentrations of antimicrobials up to 1000x higher than systemic routes, and these
large concentrations are delivered directly to the source of infection.10,40 Antimicrobials
delivered at this concentration may be effective at eliminating bacteria that are normally resistant
to lower doses of antimicrobials.12 Circumventing the systemic vasculature also prevents
delivery of high concentrations of antimicrobials to sensitive tissues and reduces their systemic
side effects. This is especially important with antimicrobial classes such as aminoglycosides or
glycopeptides that have dose-dependent ototoxicity and nephrotoxicity.41-43 Delivery of
antimicrobials from these systems is mediated through diffusion and determined by the initial
loading concentration of antimicrobials. This produces an effective release profile for infection
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prevention. Initial high concentrations of antimicrobials can eliminate pathogens that are initially
colonizing the site, and sustained lower concentrations can prevent additional microbes from
settling.
There are many local therapeutic delivery systems available on the market, but they
possess drawbacks that limit their efficacy. PMMA is the most commonly used material in the
treatment of orthopaedic infections due to its strong mechanical properties and ability to elute
therapeutics for extended periods.44 However, it never degrades in the body, and once the
therapeutic load is expended, it serves as an attachment point for bacteria to colonize. CaSO4 is
an osteoconductive, resorbable material that eliminates the need for a removal surgery. The most
common complaint with this system is the occurrence of serous wound drainage, which has been
reported to occur between 15% and 51% of cases.10,45 Collagen, a natural polymer, is a principal
component of the extracellular matrix and has been used extensively in tissue engineering and
fabrication of therapeutic delivery systems.46 The immune system recognizes this polymer and
does not elicit an immune response, and the degradation products are easily handled by the body.
Drawbacks of this material are weak mechanical properties that prevent fabrication into a
supportive construct and relatively high cost. PLA and PGA are common materials used in the
fabrication of hydrogels and tissue engineering scaffolds. An advantage of these materials is their
mechanical properties can be tailored by varying the stereoregularity of the pendant groups on
the polymer.47 The main disadvantage is the degradation products: lactic acid and glycolic acid.
These relatively strong acids elicit an inflammatory response and accelerate the degradation of
the local delivery system. Developing a local delivery system that is biocompatible, degrades to
easily handled products, and elutes active therapeutic agents is a challenging task, but chitosan
shows promise in overcoming the limitations of other therapeutic delivery systems.16,48,49
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Chitosan
Chitosan is a linear, cationic polysaccharide composed of repeating β-(1-4)-linked
glucosamine and N-acetylglucosamine subunits.15 This versatile material is principally derived
from a natural biopolymer, chitin, that composes the exoskeleton of crustaceans and to a lesser
extent the cell wall of fungi and some insects.16 Excluding cellulose, chitin is the most abundant
polysaccharide that occurs in nature and serves as an inexpensive, readily available resource.14
Several million tons of chitin are harvested annually from the exoskeleton of krill, shrimp,
lobster, and crab.15
Converting chitin to chitosan can be a harsh chemical process that ultimately involves
exposing chitin isolated from the exoskeleton shells to concentrated sodium hydroxide or
hydrochloric acid, elevated temperatures, and pressure for an extended period of time. The
conversion can also be completed using lengthier, less harsh chemical or enzymatic processes.
These methods result in deacetylation of the N-acetylglucosamine units or removal of the acetyl
groups on the polymer chain. The repeat unit for chitin mainly consists of N-acetylglucosamine
units, and may comprise 10% or less of the deacetylated glucosamine units. The consensus for
the percentage of glucosamine units required for the polymer to be considered chitosan instead of
chitin is 50%.50
The degree of deacetylation (DDA) is a defining characteristic of chitosan and has been
shown to affect important properties such as biocompatibility, degradation rate, fluid retention,
and therapeutic release kinetics.51-53 Chitosan with 50% DDA has the most rapid degradation
rate; whereas, 0% DDA chitin and 100% DDA chitosan exhibit the slowest degradation rate.
These differences can be explained by the crystallinity of the polymers. Highly crystalline
polymers are more difficult to degrade compared to amorphous polymers. Some methods to
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modify DDA are by changing processing conditions such as the concentration of sodium
hydroxide, reaction temperature, reaction time, and number of successive reactions.54-56 Another
important parameter that defines the properties of chitosan is the molecular weight of the
polymer; this property influences biodegradability, mucoadhesivity, and antimicrobial
effects.53,57,58 Mucoadhesivity increases as the molecular weight of chitosan increases due to
increased entanglements of the chitosan chains with mucous proteins. The molecular weight of
chitosan can be tailored by using chemical methods, high energy radiation, enzymatic methods,
or mechanical treatments.59-61 Mechanical methods are the most suitable for producing chitosan
due to excellent control over the molecular weight and little effect on the DDA.59 Therefore,
tailoring DDA and molecular weight of chitosan is an important consideration for fine-tuning the
properties of chitosan for specific applications.
Chitosan possesses two of the most important characteristics of a local therapeutic
delivery system: biodegradability and biocompatibility. As such, it has been developed into
many different technologies that take advantage of these properties and expand upon them. Some
examples include thin films, hydrogels, tissue scaffolds, nanoparticles, sponges, and paste.48,62-66
These systems have been developed for different therapeutic goals and implemented with some
success. However, there are many types of synthetic and natural materials available for
fabrication into therapeutic delivery systems. Each material has a distinct set of advantages and
disadvantages associated with it that limits its applications, and chitosan is not an exception. A
major advantage for chitosan is that it possesses functional groups that allow for its properties to
be modulated to the desired application. Once the chemical structure has been modified, it is no
longer referred to as chitosan but as a chitosan derivative.16
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Chitosan Derivatives
Chitosan possesses primary hydroxyl groups, secondary hydroxyl groups, and primary
amino groups that are targets for chemical reactions.16,17 The primary goal of modifying chitosan
is to retain the desirable characteristics, biocompatibility and biodegradability, while improving
characteristics pertinent to the desired application. In the case of therapeutic delivery systems,
modifications aim to tailor the release kinetics, therapeutic compatibility, solubility, and
adhesiveness.19,67-70 Modifications of chitosan can range from cleaving the polymer to grafting
long chain polymers to the backbone.17,71 A major disadvantage of having multiple functional
groups available for reaction is the potential for undesirable side reactions to occur.16,71 Side
reactions lead to the production of several minor and major products that have different
properties. In most cases functional groups can be conserved by using reversible reactions that
conjugate protecting groups to prevent undesirable reactions. Another method to reduce
heterogeneity of the final product is to use milder, targeted reaction conditions that show
selectivity for functional groups and regioselectivity for specific groups.72,73 Both methods
produce a more homogenous product that is easier to characterize and allows for a more accurate
determination of the properties of the final product.
Quaternized Chitosan
Quaternized chitosans are prepared by the addition of alkyl groups to the primary amino
group on the backbone of chitosan. By adding three constituent groups to the amino group,
chitosan acquires a permanent source of positive charge that supplements its natural cationic
properties. The prototypical polymer of this class of derivatives has three methyl groups attached
to the primary amino group. Therefore, it is commonly referred to as trimethyl chitosan (TMC).
Most synthetic pathways result in undesirable O-methylation or dimethylation of the primary
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amino group. The hydrophobic nature of these groups conflict with the hydrophilicity of the
trimethylated amino groups and lends amphoteric properties to TMC.74 The permanent cationic
character of trimethyl chitosan has been shown to enhance the antimicrobial properties75,76,
antifungal properties75,77, mucoadhesion16,78, and solubility at neutral pH74,79 compared to
chitosan. These benefits are mainly observed when trimethylation only occurs at the primary
amino group. If methylation occurs at either of the hydroxyl groups, these beneficial effects are
markedly attenuated.72,78
Methylation regioselectivity is one of the two principle properties that govern the
properties of quaternized chitosan derivatives. The other property is the degree of quaternization
(DQ), which is similar to the DDA of chitosan. DQ is a measure of the amount of primary amino
groups that have been quaternized and serves as a method for tailoring the properties of this class
of derivatives. The antibacterial activity of trimethyl chitosan has been credited to the permanent
positive charge resulting from trimethylated amino groups; this is a probable explanation for
reports of derivatives with higher DQ possessing enhanced antibacterial effects.67,80 This makes
it seem that maximizing DQ would be desirable, but increasing DQ does not always lead to
beneficial effects. There have been reports that high molecular weight trimethyl chitosan with
large DQ has cytotoxic effects.76,78 Also, there are conflicting reports on how DQ affects the
mucoadhesivity of this class of derivatives. There have been reports that increasing DQ leads to
an increase in mucoadhesivity, but the majority of reports seem to agree that it leads to decreased
mucoadhesivity.16,81 Due to varied effects of DQ on the properties of quaternized chitosans, it is
important to consider the final application when selecting the DQ.
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Graft Copolymers of Chitosan
Graft copolymers of chitosan are produced by initiating and growing chains of monomer
or grafting preformed polymers onto the backbone of chitosan. Methods to produce this class of
derivatives include free radical polymerization, polycondensation reactions, copolymerization
via grafting of preformed polymers, and other synthetic methods that possess advantages and
disadvantages.16 Derivatives of this class are highly varied and do not typically have similar
properties. The most notable graft copolymer of chitosan is produced by addition of
poly(ethylene glycol) (PEG) to the backbone. PEG is a useful polymer due to its hydrophilicity,
high solubility in water, and biocompatibility. Attaching this polymer to the backbone of
chitosan retains its biocompatibility and degradation properties while increasing the solubility of
chitosan at neutral pH and swelling ratio.82,83
Copolymers of chitosan and PEG have many applications due to the combination of both
polymers favorable properties. This class of derivatives has found use in therapeutic delivery,84
gene product delivery,85 and as wound dressings.86 A minor determinant of how adding PEG
affects the properties of chitosan is how it was attached. If the PEG was attached via an end
group, there might be an additional end group available for crosslinking or interaction with other
materials. One study investigated the efficacy of a copolymer of chitosan and PEG for delivery
of an anti-cancer drug, methotrexate.84 This combination delivery system vastly increased the
efficacy of the free drug for targeting and treating the studied tumor. Another study investigated
the effect of adding PEG to chitosan for the delivery of gene products85; the authors found that
transfection efficacy was significantly increased and was credited to a reduction in the
aggregation of DNA. These studies have investigated the effect of attaching PEG directly to
chitosan without end groups. Few studies have investigated attaching PEG with acrylate end
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groups to chitosan. The authors investigating the copolymer found that it was able to form thin
films that were more adhesive and water soluble compared to chitosan.19,86
Current Work
Orthopaedic trauma and total joint replacement patients are at high risks for contracting
an infection.25,26,32 Treating these infections is taxing and expensive for both healthcare systems
and patients.36,87 Due to the characteristics of these infections, the invading pathogens may be
refractory to systemic antimicrobials.4,28 Local delivery of antimicrobials is a popular adjunctive
treatment for infection prevention in combination with systemic antimicrobial therapy.10,88 Local
delivery systems currently used in the management of these infections have issues with
degradation properties, biocompatibility, and therapeutic options.10,44,47 Chitosan is a natural
biopolymer that has been shown to be able to degrade within the body, biocompatible, and
loaded with a breadth of therapeutics.14,15
Chitosan paste has been developed as an injectable delivery system for complex
musculoskeletal trauma. The first generation paste eluted antimicrobials for 3 days and had
limitations with in vivo biocompatibility. Future iterations improved on the biocompatibility
issue, but modifications to the system resulted in the loss of its advantageous degradation and
adhesive characteristics.20,21 Chitosan possesses reactive functional groups that make it amenable
selective chemical modification.17 Quaternized chitosan derivatives have been shown to enhance
the antibacterial properties, solubility, and mucoadhesivity compared to unmodified
chitosan.75,78,79 Copolymers of chitosan and PEG are more soluble at neutral pH, more adhesive,
and have an enhanced swelling ratio compared to chitosan alone.82,83,86 These derivatives have
advantages over unmodified chitosan that may be beneficial for local delivery systems.
Quaternized chitosan derivatives, a copolymer of chitosan and PEG, or a combination of the two
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could allow for tailored elution and degradation characteristics for use as an adjunctive local
delivery system of antimicrobials for infection prevention. The aims of this are to (1) produce a
local delivery system that elutes active antimicrobials longer than previously developed systems
with a target between 3-7 days to provide protection from bacteria during wound closure and
initial healing, (2) tailor complete degradation of the system to occur between 7-14 days to
maintain antimicrobial elution and facilitate removal before initial healing finishes, (3) retain the
biocompatibility of the parent chitosan to allow use as an infection prevention system, (4) regain
or exceed the adhesiveness of the first generation chitosan paste to prevent migration from the
wound site, and (5) maintain the injectability of the delivery system to allow for enhanced
coverage of complex musculoskeletal wounds.
Hypothesis
TMC and PEGDAc were synthesized to assess feasibility as a local delivery system. It
was hypothesized that a combination of TMC and PEGDAc could be developed into an
injectable delivery system for preventing infection in extremity injury patients with complex
musculoskeletal trauma. Research objectives were to extend elution of antimicrobial agents
compared to previously developed systems with a target between 3 and 7 days. Elution for 7
days would provide protection from bacteria during initial wound closure and dressing changes.
Another goal is to have complete degradation of the system between 7 and 14 days to allow for
initial healing of soft tissue. The final objective is to enhance the adhesive characteristics
compared to previously developed systems. Preventing migration of the delivery system from the
wound site is crucial for maintaining high concentrations of antimicrobial at the wound site.
TMC will allow degradation rate to be tailored by varying the degree of quaternization, and this
will provide a mechanism for matching degradation properties and elution kinetics of the local
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delivery system. Inclusion of PEGDAc will enhance swelling characteristics and adhesiveness of
the material; these additional properties will allow incorporation of more aqueous antimicrobial
solution and better adhesion to open wounds. Secondary objectives include maintaining
cytocompatibility with representative cell lines, injectability for easy application, and point-ofcare loading for increased treatment options.
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CHAPTER III
A degradable chitosan derivative based delivery system for local delivery of antimicrobials:
Preliminary Evaluations and Assessments
Abstract
Refined local delivery systems are needed as adjunctive treatments for severe injuries with high
infection rates, such as open fractures. Chitosan systems have been investigated as local delivery
systems of antimicrobials for orthopaedic infections but possess mismatches between elution and
degradation properties. Derivatives of chitosan were chosen that have enhanced swelling ratios
or tailorable degradation properties. A combination of trimethyl chitosan and poly(ethylene
glycol) diacrylate chitosan was developed as an injectable local delivery system. Research
objectives are eluting antimicrobials for 7 days, degradation as open fracture heals, and
remaining cytocompatible. The derivative combination eluted increased active concentrations of
vancomycin compared to the non-derivatized chitosan paste, 6 vs. 5 days. The derivative
combination degraded slower than non-derivatized in an enzymatic degradation study, 14 vs. 3
days, which increased the antimicrobial delivery profile. Cytocompatibility of the combination
with NIH3T3 fibroblast and MC3T3 pre-osteoblast cells are within the cell viability standard set
in ISO 10993-5. Combination paste requires an increased ejection force of 9.40N (vs. 0.64N),
but this force was within an acceptable injection force threshold of 80N. These preliminary
results indicate that the combination paste should be considered for further development into a
clinically useful adjunctive local delivery system for infection prevention.

Key Words
Chitosan derivatives, local delivery, infection prevention, trimethyl chitosan, injectable paste
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INTRODUCTION
Approximately 100,000 open fractures occur each year in the United States civilian
population.1 Open fractures are traumatic injuries that engage both soft and hard tissues and are
more difficult to treat compared to closed fractures due to their complex geometry, compromised
vasculature, and possible bacterial contamination. Treatment of these injuries may include
irrigation and debridement of the wound site, systemic administration of antimicrobials, and
placement of external or internal fixation devices.2,3 Despite following proper treatment
protocols, up to 50% of patients sustaining these injuries will become infected which can result
in significant complications such as nonunion, malunion, and wound necrosis.4-6 The most
prevalent pathogens that cause orthopaedic infections are Staphylococcus aureus (S. aureus),
Staphylococcus epidermidis (S. epidermidis), and Pseudomonas aeruginosa (P. aeruginosa).
These microorganisms account for nearly 75% of biofilm-based infections in medical devices.7
Necrotic tissue, devascularized bone, and fracture fixation devices are ideal substrates for
bacterial adherence and biofilm formation. Treating infected open fractures is difficult due to
compromised vasculature and irregular geometries, and may be further complicated by
antimicrobial resistance bacteria and the presence of biofilm.8-10 Therefore, infection prevention
is crucial in the management of patients with open fractures.
Local delivery of antimicrobials has become a popular adjunctive therapy in combination
with systemic antimicrobials for infection prevention.5 Local administration of therapeutic agents
reduces systemic toxicity and maximizes concentration at the injury site. Several materials have
been fabricated into local delivery systems for the treatment of orthopaedic infections over the
past several decades: poly(methyl methacrylate) (PMMA), calcium sulfate (CaSO4), and
collagen.5,11 These materials have been used clinically with some success, but they possess
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drawbacks that could be improved. PMMA is incompatible with temperature-sensitive
antimicrobials due to heat released during polymerization and requires explantation to facilitate
removal from the body.5 Unless removed in a timely manner, antimicrobials are eluted at
subtherapeutic dosages that may promote antimicrobial resistance.12 CaSO4 is a resorbable
biomaterial that eliminates the need for a removal surgery. However, the most common
complaint is the production of sterile wound drainage from degradation.13,14 Collagen is a
resorbable biopolymer and an important structural component of the extracellular matrix. Its
main drawback is the rapid release of antimicrobial agents does not correspond to its rate of
degradation within the body.5,11
Chitosan, a natural glycomaterial, is a polysaccharide that is principally derived from the
exoskeleton of crustaceans. This abundant biopolymer has been developed into a wide variety of
therapeutic delivery systems due its biocompatibility and ability to degrade within the body.15,16
Other advantages include its mucoadhesivity and intrinsic antimicrobial properties.17 Release
kinetics of antimicrobials from chitosan systems typically exhibit a bolus release and show
similar drawbacks as collagen systems.13 However, the properties of chitosan can be modified
due to the presence of reactive functional groups, and derivatives of chitosan can be specifically
produced to enhance desirable characteristics while retaining its biocompatibility and
degradation properties.17-19 Quaternized chitosans are water soluble, have enhanced antimicrobial
properties, and have been shown to degrade at the same rate or faster than unmodified
chitosan.20,21 Cross-linked chitosans have been shown to extend release kinetics and enhance
swelling ratio, but they also extend the degradation profile.22,23
In this study, we developed a blend of trimethyl chitosan (TMC) and poly(ethylene
glycol) diacrylate chitosan (PEGDAc) to combine the water solubility and degradation properties
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of TMC with the enhanced swelling ratio of PEGDAc. When the composite is hydrated with
antimicrobial solution, a paste is formed that can be used as an injectable delivery system for
preventing infection in complex musculoskeletal trauma. Toward demonstrating feasibility for
this combination as an injectable infection prevention biomaterial, elution kinetics, activity of
antimicrobials, and degradation of the composite were compared to non-derivatized chitosan
controls. Additionally, biocompatibility and injectability were evaluated against clinically
relevant standards of 70% viability and 80N of force to assess feasibility of delivery for the
complex geometry of open fractures.24,25
MATERIALS AND METHODS
Synthesis and fabrication
Two chitosan derivatives were prepared from chitosan (Chitinor AS, Norway) with a
molecular weight of 250.6 kDa and degree of deacetylation of 82.46%. The first derivative was
N-trimethyl chitosan (TMC), a quaternized chitosan derivative, and the other derivative was
poly(ethylene glycol diacrylate) chitosan (PEGDAc), a graft copolymer of chitosan. Unmodified
chitosan delivery systems previously developed in this lab were prepared using the same batch of
chitosan and used as controls.26,27
Preparation of trimethyl chitosan
TMC was synthesized according to a method adapted from Verheul et al. with minor
modification.28 This method was chosen to avoid side reactions that are present in other methods
for preparing TMC.29 Chitosan was dissolved at a concentration of 4% (w./v.) in 30.0 mL formic
acid, 40.0 mL formaldehyde, and deionized (DI) water and modified using an Eschweiler-Clarke
reaction. The solution was heated to 70°C and allowed to stir for 120 hours. The resulting
solution containing the intermediate product, dimethyl chitosan (DMC), was evaporated under

23

vacuum. This solution was gelled using 1.0M NaOH and washed with DI water. DMC was
dissolved in DI water adjusted to pH = 5 with 1.0M HCl, and dialyzed for 3 days against DI
water. The purified solution was frozen at -80°C and lyophilized for 3 days. To remove
particulates, DMC was dissolved in DI water, gelled using 1.0M NaOH, and washed with DI
water and acetone. The washed product was suspended in N-methyl-2-pyrrolidone (NMP), and
excess iodomethane was added to the solution. This solution was heated to 40°C and allowed to
stir for 72 hours. The solution was dropped in a 50:50 mixture of ethanol and diethyl ether to
precipitate the final product. TMC was separated from the solution using centrifugation and
dissolved in a 5% (w./v.) solution of NaCl. This solution was dialyzed against DI water for 3
days, frozen at -80°C, and lyophilized.
Preparation of poly(ethylene glycol diacrylate) chitosan
PEGDAc was synthesized according to the method described in Shitrit et al. with minor
modification.30 Chitosan was dissolved at 1% (w./v.) in a 1% (v./v.) solution of blended lactic
and acetic acid (3:1 ratio). This solution was stirred for 24 hours to allow the chitosan to
completely dissolve. Then, poly(ethylene glycol) diacrylate (PEGDA) with a molecular weight
of 8000 (Alfa Aesar, Massachusetts) was added to the solution at 1% (w./v.) concentration. The
solution was stirred for 15 minutes to allow the polymer to dissolve and heated to 60°C for 3
hours. The resulting solution was dialyzed against DI water for 3 days to remove unreacted
PEGDA molecules, frozen at -80°C, and lyophilized for 3 days. The freeze-dried product was
treated using 0.25M NaOH, and the pH was reduced to neutral using copious DI water. Finally,
the neutralized product was frozen at -80°C and lyophilized for 3 days.
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Grinding and reconstitution
Final lyophilized products were ground into small flakes and stored in a desiccator.
Chitosan derivatives were combined in a 3:1 weight ratio of PEGDAc to TMC. To form the
injectable delivery system, the ground products were hydrated using at a ratio of 4.5 mL of liquid
per gram of powder. Loss of product was minimized by hydrating the powder directly in syringes
using a Luer-Lock coupled system.
Preparation of controls
Two controls were prepared for comparison to the developed system: an injectable paste
and lyophilized sponges. Berretta et al. previously developed an injectable system and was
prepared according to their methods.27 Blended chitosan control paste was prepared by
dissolving 1% chitosan (w./v.) in 0.85% (v./v.) acetic acid solution and adding 1% (w./v.) PEG
(molecular weight = 8000) to the solution. This solution was frozen at -80°C, lyophilized for 3
days, and not neutralized. The PEG blended chitosan control was not mixed with either
derivatives. Chitosan sponge controls were prepared according to the methods in Noel et al. with
minor modification.26 Lyophilized sponges were prepared by dissolving 1% chitosan (w./v.) in a
1% (v./v.) blended lactic and acetic acid solution (3:1 ratio). This solution was frozen at -80°C,
lyophilized for 3 days, and treated using 1.0M NaOH. The pH of the sponges was brought to
neutral using DI water, frozen at -80°C, and lyophilized. Control sponges were hydrated using
passive absorption for evaluation.
Fourier transform infrared spectroscopy
A Nicolet iS10 (Thermo Scientific, USA) using attenuated total reflectance (ATR) was
used to collect spectra for chitosan, DMC, TMC, PEGDA, and PEGDAc. Samples were prepared
by vacuum drying at 40°C for 3 days. Data was collected using a deuterated tryglycine sulfate
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(DTGs) potassium bromide detector over the range of 525-4000 cm-1 with 64 scans and a
resolution of 2 cm-1. Ambient air was used to apply baseline corrections. Spectra were analyzed
using Thermo Scientific OMNIC Software.
Nuclear magnetic resonance spectroscopy
The 1H NMR spectra were collected using a JEOL Resonance 400 MHz NMR
spectrometer at 25°C. TMC and PEGDAc samples were dispersed at 1% (w./v.) concentration in
D2O with 0.01 mL of DCl added to dissolve the polymers. Solutions were vortexed overnight to
ensure complete dissolution.
Antimicrobial elution
Combinations of TMC and PEGDAc and non-derivatized paste were hydrated using a 5
mg/mL combination solution of vancomycin and amikacin (MP Biomedicals, USA).
Approximately 0.6 mL of hydrated paste (n = 4) was injected into cell crowns (Scaffdex,
Finland) with nylon filters (pore size = 41 µm) attached. Each sample was placed in 5 mL of
phosphate buffered saline (PBS), incubated at 37°C, and sampled daily. Upon sampling, each
sample was completely refreshed with PBS. Vancomycin was detected and quantified using a
high performance liquid chromatography (HPLC) system interfaced with a UV/Vis
spectrophotometer. Amikacin was quantified using a previously described method of pre-column
derivatization with an o-phthaldialdehyde reagent and subsequent detection with an HPLC
system using a fluorescence detector.31
Antimicrobial activity
Activity of the eluates against relevant orthopaedic pathogens S. aureus (UAMS-1;
ATCC 49230) and P. aeruginosa (PA; ATCC 27317) was evaluated using zone of inhibition
(ZOI) assays. Bacteria were grown separately overnight at 37°C in tryptic soy broth (TSB).
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Overnight growth was diluted, 1:10 for S. aureus and 1:50 for P. aeruginosa, in TSB, and 100.0
µL of these solutions was spread on tryptic soy agar plates. Blank paper discs (diameter = 6.0
mm) were hydrated with 30.0 µL of eluate and placed on the plates. These were incubated for 24
hours at 37°C and photographed. ImageJ software was used to determine the ZOI for each disc.
Enzymatic degradation
Approximately 0.3 mL (n = 3) of each system was hydrated using PBS and placed in
petri dishes. Non-derivatized neutral sponges were cut into equal parts (n = 3), hydrated with
PBS, and placed in petri dishes. Degradation solution was prepared by dissolving 1 mg/mL
lysozyme type VI (MP Biomedicals) and 100 µg/mL Normocin antibiotic/antimycotic in PBS.
Then, 5 mL of degradation solution was added to each petri dish, and samples were placed in the
incubator at 37°C. At days 1, 3, 5, 7, and 14 samples were taken, aspirated through a nylon filter
(pore size = 41 µm), and placed in an oven at 45°C. Fresh degradation solution was replaced
every other day by aspirating the old solution through a nylon filter (pore size = 41 µm) and
adding 5 mL of fresh solution. After drying, samples were weighed and compared to their initial
weight to determine degradation rate (Equation 1). Different samples were used each day due to
the destructive nature of the test.

Cytocompatibility

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 𝑑𝑑𝑑𝑑𝑑𝑑 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚

× 100

(1)

NIH3T3 fibroblast and MC3T3 pre-osteoblast cells were seeded at 1 x 104 cells/cm2 in
24-well plates and grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum and 100 µg/mL Normocin for 24 hours at 37°C and 5% CO2.
Approximately 0.3 mL (n = 3) of each paste was hydrated using sterilized PBS and injected into
cell culture inserts (Falcon, pore size = 8 µm) and placed in each well. Cells were exposed to
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eluates from the paste for 24 and 72 hours and quantified using a Cell-Titer Glo (Promega)
assay. Results were normalized as a percent viability of cells grown on blank tissue culture
plastic. Samples were sterilized with ethylene oxide gas (EtO) prior to testing.
Injectability
Injectability of the pastes was evaluated by measuring the maximum ejection force from
a standard 1 mL syringe. Approximately 0.9 mL (n = 3) of paste was hydrated using PBS and
ejected. Each syringe was placed in an Instron Universal Testing Machine (Instron) with a 500 N
load cell and programmed to compress the syringe at a constant rate of 1 mm/second to fully
eject the pastes. Force required to fully eject the pastes was measured, and maximum force
required was recorded. Syringes filled with air were used for baseline corrections.
Statistical analysis
Statistical analysis of the results was performed using Sigma Plot 14 (Systat Software).
Two way analysis of variance (ANOVA) with group and time point as the two factors, and
Student-Newman-Keuls post hoc analysis was used to determine statistical differences between
groups for degradation rate, antimicrobial elution, and relative cell viability. T-tests were used to
assess differences for injectability of the pastes. P values < 0.05 were considered to be
statistically significant.
RESULTS
Fourier transform infrared spectroscopy
Characteristic peaks were observed at 1105, 1464, and 2877 cm-1 correspond to C-O
stretching, C-H bending due to methylene groups, and C-H stretching, respectively (Figure 1).
These peaks are present in the spectra for PEGDA and PEGDAc, but they were absent or shifted
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in the non-derivatized chitosan sample. Noticeable differences were not observed between the
spectrums of DMC, TMC, and chitosan.
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FIGURE 1. ATR-FTIR absorbance spectra for I: PEGDA 8000, II: PEGDAc, and III:
unmodified chitosan. Peaks of interest are indicated, and peak at 2350 cm-1 is due to CO2.
Nuclear magnetic resonance spectroscopy
The 1NMR spectra for TMC and PEGDAc disclosed the presence and absence of
characteristic peaks. For TMC, the peak at 2.9 ppm corresponds to the dimethyl group, and the
peak at 3.2 ppm corresponds to the trimethyl group. The peak at 1.9 ppm is due to the hydrogens
of the acetyl moiety. Peaks between 3.5-4.1 ppm are due to the hydrogens present on the
chitosan backbone (Figure 2). For PEGDAc, the sharp peak at 3.5 ppm corresponds to the PEG
portion of PEGDA, and the peak at 1.9 ppm corresponds to the acetyl moiety. There is an
absence of peaks between 5.9-6.5 ppm that would represent the vinyl end group (Figure 3).30
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FIGURE 2. NMR spectra of 10 mg/mL TMC dissolved in D2O/DCl at room temperature.

FIGURE 3. NMR spectra of 10 mg/mL PEGDAc dissolved in D2O/DCl at room temperature.
Antimicrobial elution
Similar release kinetics were observed for both antimicrobials and delivery systems
(Figures 4a, 4b, 5a, and 5b). A burst release of antimicrobials was observed on day 1 for both
systems that tapered below detectable levels after day 7. Concentrations of vancomycin dipped
below the minimum inhibitory concentration (MIC) of S. aureus after day 6, and amikacin
concentrations dropped below the MIC of P. aeruginosa by day 5. Cumulative release of
vancomycin from the combination paste was 76.5 ± 13.5% and 76.4 ± 10.6% from the nonderivatized paste. Similar cumulative release profiles were observed for amikacin with the
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combination eluting 81.7 ± 13.2%, and the non-derivatized paste eluting 81.6 ± 10.3%. No
significant differences were observed between the groups, but the combination paste eluted
vancomycin at day 7 while the non-derivatized paste did not.
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FIGURE 4. In vitro elution of vancomycin. (a) full elution profile for days 1-7. (b) shows
zoomed in elution profile for days 3-7. Data are presented as mean ± standard deviation (n = 4).
* denotes significant differences from control (p < 0.05).
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FIGURE 5. In vitro elution of amikacin. (a) full elution profile for days 1-7. (b) shows zoomed
in elution profile for days 3-7. Data are presented as mean ± standard deviation (n = 4).
Antimicrobial activity
Large zones (> 10mm) were observed for both systems on day 1 that tapered off to
clinically irrelevant zones (< 1mm). Combination paste inhibited growth of S. aureus for 6 days
while the non-derivatized paste only prevented growth for 5 days (Table 1). Both combination
and non-derivatized paste produced zones for 5 days against P. aeruginosa (Table 2).
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TABLE 1. Zone of inhibition results for S. aureus. Zones greater than 10mm are indicated with
+++, larger than 6mm are indicated with ++, larger than 1mm are indicated with +, and smaller
than 1mm are indicated with -.

Formulation
25TMC : 75
PEGDAC
Control

Eluate Sample Time (Day)
1

2

3

4

5

6

7

10.1 ± 0.8
+++
10.0 ± 0.6
+++

8.3 ± 0.5
++
8.1 ± 0.7
++

6.7 ± 0.5
++
5.1 ± 0.5
+

4.4 ± 0.4
+
3.6 ± 0.8
+

2.3 ± 0.5
+
2.3 ± 1.1
+

1.4 ± 0.4
+
0.5 ± 0.9
-

0.0 ± 0.0
0.0 ± 0.0
-

TABLE 2. Zone of inhibition results for P. aeruginosa. Zones greater than 10mm are indicated
with +++, larger than 6mm are indicated with ++, larger than 1mm are indicated with +, and
smaller than 1mm are indicated with -.

Formulation
25TMC : 75
PEGDAC
Control

Eluate Sample Time (Day)
1

2

3

4

5

6

7

13.1 ± 0.5
+++
14.0 ± 0.4
+++

9.9 ± 0.8
++
10.5 ± 0.9
+++

7.4 ± 0.8
++
6.0 ± 1.9
+

3.5 ± 0.7
+
2.9 ± 1.1
+

1.5 ± 0.4
+
1.2 ± 0.7
+

0.0 ± 0.0
0.0 ± 0.0
-

0.0 ± 0.0
0.0 ± 0.0
-

Enzymatic degradation
Combination paste was almost completely dissolved/degraded by day 14 with 5.55 ±
1.93% remaining of the original mass (Figure 6). A decrease in mass was observed for each day
which is in contrast to the non-derivatized paste. Non-derivatized paste was degraded to 10% of
its original mass by day 5 and remained there for the duration. The non-derivatized sponge did
not experience any observable degradation. By day 14, it weighed 138.26 ± 2.07% of its original
mass, and this is possibly due to the salts in PBS being retained and crystallizing in the sponge.
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FIGURE 6. In vitro enzymatic degradation of chitosan-based delivery systems. Results are
presented as mean ± standard deviation (n = 3). * denotes significant differences from control (p
< 0.05).
Cytocompatibility
Each of the delivery systems evaluated were cytocompatible according the criteria
established in ISO 10993-5.24 Cellular viability was based on cells not exposed to chitosan-based
biomaterials. Viability of NIH3T3 fibroblasts cells was reduced by approximately 12 and 13%
after being exposed to combination paste for 24 and 72 hours, respectively (Figure 7). There was
no reduction in viability for the non-derivatized sponge and paste after 24 hours, but there was
approximately a 25 and 30% reduction after 72 hours. Similar results were observed with
MC3T3 pre-osteoblast cells with combination paste producing a 4 and 17% reduction in viability
on days 1 and 3, respectively (Figure 8). Again, there was not a reduction in viability for the nonderivatized sponge and paste after 24 hours, but there was a reduction of 6 and 16% after 72
hours.
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FIGURE 7. In vitro cytocompatibility evaluation with NIH3T3 fibroblast cells. Results are
presented as mean ± standard deviation normalized to cells grown on blank tissue culture plastic
(n = 3). * denotes significant differences from blank tissue culture plastic (p < 0.05). The black
bar shows the threshold value outlined in ISO 10993-5 for cytocompatibility.
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FIGURE 8. In vitro cytocompatibility evaluation with MC3T3 pre-osteoblast cells. Results are
presented as mean ± standard deviation normalized to cells grown on blank tissue culture plastic
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(n = 3). * denotes significant differences from blank tissue culture plastic (p < 0.05). The black
bar shows the threshold value outlined in ISO 10993-5 for cytocompatibility.
Injectability
After applying baseline corrections, non-derivatized paste required 0.64 ± 0.22N to eject,
and the combination paste required 9.40 ± 0.83N (Figure 9). Both of the evaluated injectable
delivery systems are below clinically relevant values for ejection force.

Maximum Ejection Force (N)

12.00

*

10.00
8.00
6.00
4.00
2.00
0.00

25TMC : 75PEGDAc

Control

Formulation

FIGURE 9. Injectability assessment of combination paste. Results are presented as mean ±
standard deviation (n = 3). * denotes significant differences from control (p < 0.05).
DISCUSSION
This study sought to determine elution, degradation, and injectability of a derivatized
chitosan paste composite containing TMC and PEGDAc to assess feasibility as an injectable
local delivery system for antimicrobials. The combination exhibited an extended elution profile
of vancomycin and increased degradation time compared to the non-derivatized paste without
sacrificing the injectability or cytocompatibility of the delivery system. These enhanced
properties may be due to the characteristics of the selected chitosan derivatives.29,32 These
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preliminary results indicate that the combination of TMC and PEGDAc should be considered for
further investigation as a local delivery system for use in infection prevention in severe injuries
with high infection rates.
Results from the FTIR and NMR analyses provided evidence that the modifications were
successfully performed. PEGDAc required both FTIR and NMR results to provide confirmation
that the synthesis was performed successfully. FTIR spectra showed peaks that were
representative of ether bonds in PEGDA and PEGDAc, and these were absent in unmodified
chitosan. NMR demonstrated that PEG was present in the polymer by the peak at 3.5 ppm. The
absence of a group of peaks between 5.9 – 6.5 ppm is indicative that there were no free acrylate
groups present.30 This may indicate that all of the PEGDA molecules present are cross-linking
the chitosan backbone. NMR results alone provided evidence that TMC was successfully
synthesized. Peaks at 2.9 ppm and 3.2 ppm were assigned to the dimethyl and trimethyl groups,
respectively. Sharp peaks were absent at 3.4 and 3.5 ppm which would indicate that side
reactions at the hydroxyl groups did not occur.28 However, there was evidence that residual NMP
was still present in TMC.
A primary goal of this research was to reduce the mismatch between elution kinetics and
degradation rates that affect chitosan-based delivery systems.5 Elution kinetics for these systems
typically exhibit an initial bolus release that is followed by low levels of release until the system
is degraded.27,33 PEGDA has previously been investigated as a cross-linked hydrogel and a crosslinking agent with a variety of systems to sustain drug delivery.23,32,34 In preliminary work not
contained in this manuscript, our group showed that PEGDAc had twice the swelling ratio of
unmodified chitosan, and other groups have produced similar results.23,32 This could help explain
the extended release profile observed compared to unmodified chitosan and other injectable
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chitosan paste studies.27,35 Chen et al. investigated a complex of thiolated chitosan, PEGDA, and
β-glycerophosphate as an injectable hydrogel.23 Their study showed an extended release profile
of a model protein that exhibited a tapered bolus release. The tapered release may be due to the
size of the protein which would have a lower diffusion coefficient.32
MIC values reported in this study were lab generated values produced by exposing the
bacteria to serial dilutions of the antimicrobials used. Activity observed for eluate samples
indicate that incorporation of antimicrobials into the system did not inactivate them. Chitosan has
been reported to possess antimicrobial properties, and quaternized chitosan derivatives, such as
TMC, have been shown to have enhanced antimicrobial effects compared to chitosan.15,21,36,37
The boost in activity observed against P. aeruginosa could possibly be due to an additive
antimicrobial effect between amikacin and TMC, but the antimicrobial activity of the delivery
system was not evaluated in this study.
Previous studies evaluated the release of vancomycin and amikacin from unmodified
chitosan pastes for 3 days, but degradation properties for these systems did not match their
elution kinetics. Berretta et al. showed almost complete degradation after day 2, and Rhodes et
al. showed continued degradation out to day 10 which was their final time point.27,35 Preliminary
evaluations demonstrated that increasing the reaction time from 24 to 72 hours slowed the
degradation rate of TMC. Previously developed systems degraded too rapidly, and it was
determined that the degradation rate needed to be slowed.27 Extended degradation of the system
under investigation could be due to a combination of the increased molecular weight of TMC
and the cross-linking of PEGDAc.38 The 14 day degradation was within the time frame of initial
healing, but this may mean that the material would remain after antimicrobials were expended.
This could be ameliorated by using TMC that had been reacted for less time, Concentrations of
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lysozyme used in this study were higher than physiological levels, and this might indicate that it
would take longer than 14 days to degrade.39 However, Stinner et al. demonstrated that chitosan
sponges were almost completely degraded in an in vivo model of infection in 42 hours. Whereas,
in this study, there was no measureable degradation after two weeks. In vitro evaluations lack the
complexity to accurately mimic clinical scenarios, and this makes translation of in vitro
degradation results difficult to translate to in vivo degradation time.
Another goal was to maintain the biocompatibility of chitosan after derivatization. Early
studies of TMC reported that this material was cytotoxic, and that increasing DQ enhanced the
cytotoxic effects.21,40,41 Synthetic methods used to prepare TMC for the studies that showed
cytotoxicity produced methylation at the amino and hydroxyl groups. More recent evaluations
use synthetic procedures that specifically target the amino group and report minimal to no
cytotoxic effects.42-44 Mazzoccoli et al. reported that concentrations of PEGDA between 20-40%
weight percent reduce cellular viability by 20-64% as the concentration increased.45 PEGDAc
produced in this study was manufactured using PEGDA at a 1% weight percentage and showed
no cytotoxicity in preliminary studies. The apparent reduction in viability for each group and
between days was higher than expected. It was noted during the experiment that cell culture
media turned pinker for the non-derivatized sponge and yellower for non-derivatized paste,
which would indicate increased alkalinity and acidity, respectively. Combination paste absorbed
some of the media and could have sequestered growth factors from the cell culture media, or
residual solvent could have been leached out of the device. Also, these evaluations used a static
fluid flow model that would result in extended exposure of the cells to the materials.
Preparation of an injectable delivery system offers distinct advantages over other systems
currently used for the treatment of open fractures. Hydration immediately prior to application
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allows for a clinician to choose which antimicrobials are incorporated. Also, the hydration ratio
can be tailored to modify the injectability properties. By hydrating paste with more aqueous
antimicrobial solution, the injection force may be lowered and more antimicrobials can be
delivered. MacDonald et al. determined the maximum ejection force of female healthcare
workers using a standard chuck grip to be 79.5N.25 Force values reported in this study are almost
10 times lower than this threshold value. Previous studies that have investigated injectable
chitosan paste reported values for ejection force ranging from 30-150N.27,35 Injectability of the
system allows for complete coverage of open fractures that may possess complex geometries.
This is an advantage over other delivery systems that are not able to conform to these wounds.
CONCLUSIONS
TMC and PEGDAc were synthesized, characterized, and developed into an injectable
paste. In vitro evaluations indicate that the combination of TMC and PEGDAc may be developed
into an improved local delivery system for infection prevention. The derivative combination’s
ability to elute active concentrations of vancomycin and amikacin, cytocompatibility with
representative cell lines, and injectability through standard 1 mL syringes demonstrates its
feasibility as an injectable antimicrobial delivery system. Capability to elute antimicrobials
beyond 3 days make the system applicable for infection prevention in open fractures, and
degradability within 14 days facilitates removal in a similar time frame to initial healing of these
injuries. Injectability and degradability of the system provides a distinct advantage over other
systems such as PMMA or CaSO4 currently used for open fractures. Future studies will
investigate the clinical potential of this system by using in vivo assessments for biocompatibility
and infection prevention efficacy.
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CHAPTER IV
DISCUSSION
The purpose of this study was to evaluate two chitosan derivatives, TMC and PEGDAc,
as potential local antimicrobial delivery systems for infection prevention. Initial evaluations
demonstrated that a combination of the two derivatives was superior to either one alone
(Appendix B), and that a weight ratio of 75% PEGDAc 25% TMC was superior to both 50%
PEGDAc 50% TMC and 25% PEGDAc 75% TMC (Appendix C). Efficacy of the combination
was determined by evaluating elution kinetics of vancomycin and amikacin, activity of eluted
antimicrobials, enzymatic degradation characteristics, cytocompatibility with representative cell
lines, injectability from 1 mL syringes, and adhesivity to muscle tissue (Appendix E). Combining
TMC and PEGDAc resulted in elution of active vancomycin and amikacin for 6 and 5 days and
successfully met the first objective of extending elution. Increasing the reaction time for
fabrication of TMC and cross-linking chitosan with PEGDA resulted in complete degradation by
day 14; this is at the later end of the criteria established in the second research objective.
Derivatization of chitosan did not result in any cytotoxicity according to ISO 10993-5.
Cytocompatibility evaluations were performed with cell lines representative of tissues present in
open fractures according to the third research objective. Incorporation of cross-linking and a
quaternized moiety increased adhesivity compared to previous iterations of chitosan paste in line
with the fourth research objective. Injectability characteristics of the combination of TMC and
PEGDAc were conserved and approximately 10% of a benchmark force in accordance with
research objective five. Enhanced properties observed for the combination paste are likely due to
the properties of the derivatives.16,19 These preliminary evaluations indicate that the combination
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of PEGDAc and TMC has much potential to be developed for local delivery of antimicrobials to
prevent infection.
Results from the FTIR and NMR analyses provided evidence that the synthesis of TMC
and PEGDAc were successfully performed. NMR spectroscopy was used to characterize TMC,
obtain a quantitative value for DQ, and assess if O-methylation had occurred. The synthetic
procedure used to produce TMC was adapted from previous methods outlined in Verheul et al.72
The authors reported a linear relationship between 40-60% DQ and reaction time of 24-72 hours.
While TMC produced in this study was allowed to react for 72 hours under similar conditions to
Verheul et al, the low DQ of 12% in the present study conflicts with the linear relationship
reported. DQ was calculated using previous methods to be 12% and was lower than expected,
and there was no evidence of O-methylation.89 . This could possibly be explained by the
differences in molecular weight and DDA of the starting materials. Verheul et al. used chitosan
with a molecular weight of 42 kDa and DDA of 93%, and the chitosan used in this study had a
molecular weight of 250.6 kDa and DDA of 82.46%. The conversion of dimethyl chitosan to
trimethyl chitosan calls for iodomethane to be added in excess, and the amount called for in
Verheul et al. was used. This may not have provided iodomethane in excess to produce the
desired DQ. FTIR and NMR analysis were used to provide evidence that PEGDAc was
successfully synthesized. In the FTIR spectra, characteristic peaks were observed at 1105, 1464,
and 2877 cm-1 and correspond to C-O stretching, methylene C-H bending, and C-H stretching,
respectively. PEGDA and PEGDAc possessed these peaks that are characteristic of ethers, and
they were not present in chitosan. NMR analysis demonstrated that PEG was present in the
polymer by the peak at 3.5 ppm. The absence of a peak group between 5.9-6.5 ppm indicates the
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absence of free acrylate groups.19 This may indicate that all of the PEGDA residues are crosslinking the chitosan backbone, and that none of the acrylated PEG chains are pendant groups.
Combining TMC and PEGDAc was designed to extend the elution kinetics compared to
previously developed chitosan pastes. This goal was established to ameliorate the mismatch
between elution and degradation that affect local delivery systems.10,88 Chitosan-based systems
typically exhibit an initial bolus release that is followed by low levels of release.21,90 Berretta et
al. and Rhodes et al. previously worked on different formulations of unmodified chitosan paste
and showed elution of active vancomycin and amikacin for 3 days.20,21 Huang et al. and Hoque et
al. investigated chitosan derivative based hydrogels that eluted vancomycin for 7 and 14 days,
respectively.91,92 Huang et al. and Hoque et al. used Schiff base reactions to covalently attach
vancomycin to chitosan. This could possibly explain the extended release profile observed in
these studies, and the reduction observed for cumulative release profiles, 50% and 60%,
respectively. Elution kinetics for the combination paste lasted for 7 days, and there was a
cumulative release of approximately 76% of vancomycin and 82% of amikacin. This could be
due to the PEGDAc component of the paste. PEGDA has been investigated as a cross-linked
hydrogel and a cross-linking agent with different local delivery systems to sustain therapeutic
delivery.83,93,94 Preliminary studies demonstrated that PEGDAc had twice the swelling ratio
compared to unmodified chitosan (Appendix A), and other groups have produced similar
results.83,93 Chen et al. investigated a complex of thiolated chitosan, PEGDA, and βglycerophosphate as an injectable hydrogel.83 Their study showed an extended release profile of
a model protein that exhibited an attenuated burst release. The evaluated systems were only
loaded with two classes of antimicrobials, and this limits the ability to generalize these results to
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other classes of antimicrobials. Vancomycin and amikacin were chosen because they are used in
the management of patients with complex musculoskeletal injuries or MRSA infections.4,38
MIC values used for reference in the elution study were lab generated values that were
produced using serial dilutions of the antimicrobials. The observed activity indicates that
incorporation of aqueous antimicrobial solution did not diminish their antimicrobial effects.
Chitosan has been reported to possess antimicrobial properties, and quaternized chitosan
derivatives, such as TMC, have been shown to have enhanced antimicrobial effects.15,80,95
Additional activity observed against P. aeruginosa beyond where the MIC was reached could be
due to an additive effect between TMC and amikacin. Zhang et al. and Wahid et al. investigated
chitosan derivative based hydrogels that displayed antimicrobial effects.96,97 Wahid et al.
provided evidence that the antimicrobial effect was due to increased concentrations of zinc ions,
but Zhang et al. showed that the antimicrobial activity could be attributed to quaternized
chitosan.
Degradation of chitosan-based delivery systems is a major advantage over PMMA and
CaSO4, but matching elution and degradation properties is difficult. Previous studies of chitosan
paste demonstrated elution of antimicrobials for 3 days, but degradation properties did not match
their elution kinetics. Berretta et al. showed almost complete degradation after day 2, and Rhodes
et al. showed continue degradation out to their final time point of 10 days.20,21 Preliminary
evaluations demonstrated that degradation of TMC could be slowed by increasing the reaction
time for 24 to 72 hours. Degradation of previously developed systems was too rapid, and this led
to incorporation of TMC that had been reacted for longer.21 Enhanced molecular weight of TMC
and the cross-linked structure of PEGDAc could be contributing to the enhanced degradation
time. The 14 day degradation observed for this system allows for antimicrobials to be delivered
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and complete degradation to occur as initial healing ceased. Degradation time could be shortened
by exchanging the TMC for one that had been reacted for less time. Degradation solution used in
this study had a lysozyme concentration of 1 mg/mL which is much higher than physiological
levels.98 Other factors could affect the in vivo degradation rate, and this makes translating in vitro
results difficult to physiological degradation. Another limitation was the exclusive use of in vitro
assessments for the efficacy and biocompatibility of this system. In vitro evaluations lack the
complexity to accurately mimic clinical scenarios, but they are invaluable models for collecting
preliminary data during initial evaluations.
Biomaterials used in infection prevention need to demonstrate cytocompatibility before
they can be implemented. Combination paste showed a reduction in relative cell viability
compared to cells grown on blank tissue culture plastic, but the relative viability remained above
the standard of 70% viability.99 Preliminary study results demonstrated that the DQ of TMC
could be modified to control the degradation rate without decreasing cytocompatibility
(Appendix A). This contradicts early studies with TMC reporting that the material was cytotoxic,
with increasing cytotoxicity as DQ increased.80,100,101 However, the synthetic methods used to
prepare the TMC used in studies that reported cytotoxicity produced non-specific methylation of
both the amine and hydroxyl groups. More recent evaluations use synthetic procedures that target
the amine group to eliminate the cytotoxicity of TMC.78,102,103 Preliminary evaluations appeared
to show that increasing the content of TMC decreased cytocompatibility, but the apparent
differences between the groups were not significant (Appendix C). Preliminary results also
demonstrated that PEGDAc did not lead to an increase in cytotoxicity and may have exerted a
pro-proliferative effect on NIH3T3 fibroblasts compared to controls (Appendix A). Mazzoccoli
et al. reported that concentrations of PEGDA between 20-40% weight percent reduced cellular
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viability by 20-64% as concentration increased.104 PEGDAc evaluated in this study was
manufactured using PEGDA at 1% weight percentage, and there was no evidence of cytotoxicity
in preliminary studies. Observations noted during this study were that the non-derivatized sponge
and non-derivatized paste produced a change in color of the cell culture media with pH indicator.
Non-derivatized sponge turned the media pink which would indicate increased alkalinity due to
the sponges not being completely neutralized. Non-derivatized paste turned the cell culture
media yellow, which indicates increased acidity, likely due to the acetic acid content. Reduced
cell viability for the combination paste could be due to residual solvents remaining in the system.
Combination paste also absorbed some of the media, which could have resulted in sequestering
of growth factors from the media. A limitation of this evaluation is that static fluid flow
conditions result in extended exposure of cells to materials and solvents, and thus may not
accurately predict cell response in an in vivo wound.
Injectable delivery systems provide complete wound coverage that other systems
currently used in the management of complex musculoskeletal trauma such as PMMA and
CaSO4 do not offer. Hydration immediately prior to application allows for a clinician to
incorporate their choice of antimicrobials depending on the suspected bacteria, and the hydration
ratio can be adjusted to modify the injectability. By providing more aqueous antimicrobial
solution, the force required to eject the paste may be decreased and increases the amount of
antimicrobials available. MacDonald et al. determined the maximum ejection force of female
healthcare workers using several different grip methods to range from 79.5-104.7N. Force values
reported in this study are lower than this threshold value. Previous studies that have investigated
injectable chitosan paste report values for ejection force ranging from 30-150N. 20,21 Injectability
of the system allows for complete coverage of open fractures that may have complex geometries.
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However, coverage may not be maintained if the delivery system does not adhere to the wound
site and migrates. TMC and PEGDAc have been reported to have enhanced mucoadhesive
properties compared to chitosan.19,105 Pardeshi et al. reported a 3.4-folds increase in adhesivity
for TMC compared to chitosan and was attributed to ionic interactions between TMC and mucin
proteins.105 Shitrit et al. demonstrated a 3-fold increase in adhesivity for PEGDAc, and the
authors attributed this to entanglement with PEGDA chains and a Michael addition reaction
between free acrylate groups and mucin proteins.19 Combination paste incorporates both of these
moieties, and this could explain the enhanced adhesion observed compared to the nonderivatized chitosan paste (Appendix E). Combination paste can easily be removed by conditions
similar to irrigation performed in the management of complex musculoskeletal trauma. Whereas,
the non-derivatized paste was resistant to removal by PBS irrigation, and principally removed by
gravity.
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CHAPTER V
CONCLUSIONS
TMC and PEGDAc were successfully synthesized, characterized, and developed into an
injectable paste. Initial studies were performed to determine the optimal combination of TMC
and PEGDAc according to preliminary elution and cytocompatibility results (Appendices A, B,
and C). In vitro evaluations indicate that weight percentages of PEGDAc and TMC can be
adjusted to achieve target goals for elution, degradation, and cytocompatibility. In addition to the
capability to elute antimicrobials, degradability, and cytocompatibility, combination paste is
injectable through standard 1 mL syringes and adheres to muscle tissue, demonstrating its
feasibility as an injectable delivery system. Elution kinetics lasting longer than 3 days makes the
system applicable for protecting open fractures from infection during wound closure and
dressing changes. Capability to degrade within 14 days facilitates removal from these wounds in
a similar time frame to initial healing, and cytocompatibility allows the combination to be used
as an infection prevention biomaterial without eliciting deleterious adverse effects. Injectability
provides greater wound coverage which is an advantage over other delivery systems currently
used in the management of open fractures such as PMMA or CaSO4. Enhanced mucoadhesion is
an improvement over previously developed chitosan pastes and reduces migration of the delivery
system from the wound site. These in vitro evaluations indicate that the combination of TMC and
PEGDAc has potential to be developed into a local delivery systems for infection prevention in
complex musculoskeletal trauma.
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CHAPTER VI
FUTURE WORK
Future evaluations should further investigate the nature of how PEGDA interacts with
chitosan. The initial idea was that PEGDA chains would freely hang from the backbone of
chitosan and allow free acrylate groups to react with mucin proteins. Some of the chains may be
freely hanging, but it is likely that the majority of the PEG chains are acting as cross-linking
agents, which is evidenced by the enhanced swelling ratio of PEGDAc and the absence of
acrylate groups in the NMR spectra. Another study should investigate the effects of adding
additional iodomethane during the synthesis of TMC. This may address the lower than expected
DQ observed. Also, additional purification steps should be incorporated to remove residual NMP
from TMC.
Chitosan used to synthesize TMC and PEGDAc was chosen because it had been
previously used to fabricate other local delivery systems. DDA and molecular weight are
important parameters of chitosan that helps to determine its properties. Modification of these two
parameters allows for tailoring of the properties chitosan before derivatization and may produce
a more efficacious delivery system. Furthermore, this study systematically investigated a limited
number of formulations. Combinations were chosen by mixing the desired components in a
50:50 weight ratios and adjusted by further 50:50 splitting of the two components. Following this
scheme, a 62.5% PEGDAc 37.5% TMC and an 87.5% PEGDAc 12.5% TMC should be
evaluated to determine their characteristics. All evaluations were performed using a hydration
ratio of 4.5 mL of solution per gram of dried paste based on preliminary studies. Increasing the
hydration ratio of this system may provide a method to reduce ejection force and increase
antimicrobial loading, thus enhancing injectability and extending elution.
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Evaluation performed for this study could be further expanded to provide a more robust
characterization of the local delivery system. Vancomycin and amikacin were chosen as
antimicrobials since they are commonly used in the prophylaxis of complex musculoskeletal
trauma and in combination have activity against Gram positive and Gram negative bacteria.
Future studies may determine elution kinetics of other antimicrobials, such as tetracyclines,
macrolides, and first and second generation cephalosporins. In a similar vein, future studies
could evaluate efficacy of the delivery system in treating other pathogenic bacteria, such as
methicillin resistant strains of S. aureus, the enterococci genus, and Acinetobacter baumannii.
While we have investigated chitosan derivatives as antimicrobial delivery systems in this work,
the possible additive antimicrobial effect between TMC and amikacin could be explored in
future microbiological investigations. Degradation characteristics of the evaluated system did not
meet the target of 14 days, and this could be ameliorated by using TMC that had been reacted for
less time than TMC used in this study. Cytocompatibility evaluations in this study were limited
to cells representative of connective tissue and bone tissue, but future studies could explore more
in depth inflammatory responses that could be triggered by the combination of chitosan
derivatives. Additional cytocompatibility studies will investigate the effects on cellular viability
by incorporating antimicrobials into the system. Injectability was assessed from standard 1 mL
syringes for application to external injuries, but future studies will investigate delivery through
different gauge needles for subcutaneous applications.
Future studies for the evaluated combination of PEGDAc and TMC will incorporate in
vivo evaluations of biocompatibility and infection prevention efficacy. A rodent model will be
used to evaluate the safety of the device when incorporated into a living system without infection
present. If the delivery system is proven to be biocompatible, its efficacy can be evaluated in an
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in vivo model of infection prevention. Early studies will focus on preventing infection from
occurring by placing the delivery system alongside bacteria before they establish an infection.
Later studies will focus on eliminating an already established infection. These studies would
have bacteria inoculated prior to placement of the local delivery system with infection already
established.
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APPENDIX A: Preliminary Refinement of TMC and PEGDAc
Rationale
The characteristics of TMC and PEGDAc can be adjusted by modifying the reaction
conditions. TMC can be tailored by varying the DQ to affect properties such as mucoadhesivity,
solubility, and antibacterial activity.70,76,79 The synthetic procedure used to manufacture TMC in
this study is able to control DQ by changing the duration of reaction.72 PEGDAc can be modified
by adjusting the molar ratio of PEGDA molecules to amine groups on chitosan. This ratio has
been demonstrated to affect swelling ratio, mucoadhesivity, and cytocompatibility.19,93,104
Previous studies by Verheul et al. and Shitrit et al. were used to determine initial reaction
conditions, and further modifications were performed after initial evaluations demonstrated
success. Different groups of TMC were produced by changing the reaction time for each group
to 24, 48, or 72 hours. PEGDAc groups were synthesized by modifying the molar ratio to 23.5,
47, or 94 free amine groups to PEGDA molecules. Three varieties of each derivative were
synthesized to determine if DQ or the molar ratio of PEGDA to amine groups had an effect on
antimicrobial elution, degradation rate, swelling ratio, or cytocompatibility.
Antimicrobial elution
Lyophilized constructs (n = 4) of TMC and PEGDAc were quartered and hydrated for 2
minutes using a 1 mg/mL solution of vancomycin. Each quarter was added to a petri dish with 5
mL of PBS and placed in an incubator at 37°C. Sampling was performed daily for 7 days with
complete refreshment of PBS at each time point. Vancomycin was detected and quantified using
an HPLC system interfaced with a UV/Vis spectrophotometer. Statistical analysis was performed
using one way ANOVA with a SNK post-hoc test to perform comparisons between groups.
Differences were considered significant if p-values were less than 0.05.
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FIGURE 10. Preliminary in vitro elution results of vancomycin from TMC groups. Data are
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presented as mean ± standard deviation. * denotes significant differences from other groups.
70

PEGDAc 23.5

60

PEGDAc 47
PEGDAc 94

50
40
30
20
10
0

1

2

3

Time (Days)

FIGURE 11. Preliminary in vitro elution results of vancomycin from PEGDAc groups. Data are
presented as mean ± standard deviation. * denotes significant differences from other groups.
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Oxidative degradation
Five lyophilized sponges from each group were quartered (n = 4), weighed, and hydrated
for 2 minutes in PBS. Samples were immersed in an oxidative degradation solution consisting of
0.1M CoCl2•6H2O and 3% H2O2.106 TMC groups were sampled at 1, 2, 3, 4, and 6 hours by
removal from the solution, rinsing with PBS, and drying in a vacuum oven at 45°C. PEGDAc
groups were sampled in a similar manner at 0.5, 1, 1.5, 2, and 3 hours. After samples dried for 3
days, they were weighed to calculate percent remaining. Statistical analysis was performed using
one way ANOVA with a SNK post-hoc test to perform comparisons between groups.
Differences were considered significant if p-values were less than 0.05.
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FIGURE 12. Preliminary in vitro accelerated degradation study of TMC groups. Data are
presented as mean ± standard deviation. * denotes significant difference between each group.
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FIGURE 13. Preliminary in vitro accelerated degradation evaluation of PEGDA groups. Data
are presented as mean ± standard deviation. * denotes significant difference from each group.
Swelling ratio
Sponges from each group were quartered (n = 4), weighed, and hydrated in PBS for 2
minutes. Excess fluid was allowed to drip off before obtaining the wet mass. Fluid uptake was
calculated as the difference between the wet and dry masses. Swelling ratio was calculated by
normalizing the fluid uptake to the initial mass. Statistical analysis was performed using one way
ANOVA with a SNK post-hoc test to perform comparisons between groups. Differences were
considered significant if p-values were less than 0.05.
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FIGURE 14. Preliminary in vitro swelling ratio results of TMC groups. Data are presented as
mean ± standard deviation. * denotes significant differences from each group.
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FIGURE 15. Preliminary in vitro swelling ratio results of PEGDAc groups. Data are presented
as mean ± standard deviation. * denotes significant differences from each group.
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Cytocompatibility
NIH3T3 fibroblasts were seeded at 104 cells/cm2 in 24-well plates and grown in DMEM
supplemented with 10% FBS and 100 µg/mL of Normocin for 24 hours. Coupons (diameter =
6mm) were punched from each derivative, placed in cell culture inserts (pore size = 8um), and
placed in each well. Cells were exposed to the coupons for 24 hours and quantified using CellTiter Glo assay. Results were expressed as a percentage of cells grown on blank tissue culture
plastic. Statistical analysis was performed using one way ANOVA with a SNK post-hoc test to
perform comparisons between groups. Differences were considered significant if p-values were
less than 0.05.
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FIGURE 16. Preliminary in vitro cytocompatibility results with NIH3T3 fibroblasts for TMC
groups. Data are normalized to cells grown on blank tissue culture plastic and represented as a
mean ± standard deviation. * denotes statistical significance from all groups.
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FIGURE 17. Preliminary in vitro cytocompatibility results with NIH3T3 fibroblasts for
PEGDAc groups. Data are normalized to cells grown on blank tissue culture plastic and
represented as a mean ± standard deviation. * denotes statistical significance from all groups.
Conclusion
All TMC formulations were able to elute antimicrobials (Figure 8), degradable in an
oxidative environment (Figure 10), uptake fluid (Figure 12), and cytocompatible with cells
representative of connective tissue (Figure 14). The only significant differences observed
between the three formulations were in the degradation study. TMC 48 and TMC 72 lasted
significantly longer than TMC 24. TMC 72 appeared to last longer than TMC 48, but this
difference was not significant. Each PEGDAc formulation was found to be able to elute
antimicrobials (Figure 9), degrade in an oxidative environment (Figure 11), uptake fluid (Figure
13), and not be cytotoxic to NIH3T3 fibroblasts (Figure 15). No significant differences were
observed between the PEGDAc formulations in any of the evaluations. Previous paste
formulations degraded before they could deliver their antimicrobial payload, and it would be
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advantageous to extend the degradation profile to match the elution properties. Therefore, TMC
72 and PEGDAc 47 were chosen for continued evaluation.
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APPENDIX B: Preliminary Paste Combination Evaluations
Rationale
TMC and PEGDAc show promise as lyophilized sponges for local antimicrobial delivery,
but their efficacy as paste delivery systems still needed to be evaluated. Using an injectable paste
over a lyophilized sponge offers several advantages: enhanced wound coverage for complex
musculoskeletal injuries, decreased diffusion distance of antimicrobials, and multiple starting
products can be mixed to obtain desired properties. Wound coverage and decreased diffusion
distance have already been discussed, but the concept of mixing different starting products has
not been evaluated. Previous evaluations showed that TMC had an extended degradation profile
compared to unmodified chitosan, and that PEGDAc had twice the swelling ratio compared to
unmodified chitosan. Each derivative alone, a combination of the derivatives, a previously
developed paste21, and combinations of the previous paste and derivatives were evaluated for
their ability to elute antimicrobials and cytocompatibility with NIH3T3 fibroblasts.
Antimicrobial elution
Approximately 600 mg of each paste variety was hydrated using a 5 mg/mL solution of
vancomycin. Combinations were prepared by mixing 300 mg of the respective dried materials.
Dried powder was hydrated using a ratio of 4.5 mL solution per gram of dried powder except for
PEGDAc alone, which required 7.0 mL solution per gram. Approximately 0.6 mL of hydrated
paste (n = 4) was injected into cell crowns (Scaffdex) with nylon filters (pore size = 41 µm)
attached. Each sample was placed in 5 mL of PBS, incubated at 37°C, and sampled daily. Upon
sampling, each sample was completely refreshed with PBS. Vancomycin was detected and
quantified using an HPLC system interfaced with a UV/Vis spectrophotometer. Statistical
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analysis was performed using one way ANOVA with a SNK post-hoc test to perform between
group comparisons. Differences were considered significant if p-values were less than 0.05.
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FIGURE 18. Full scale (Days 1-7) preliminary in vitro elution results of vancomycin from
chitosan derivative combinations pastes. Data are presented as mean ± standard deviation. *
denotes significantly higher concentrations compared to all other groups.
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FIGURE 19. Zoomed in (Days 3-7) preliminary in vitro elution results of vancomycin from
chitosan derivative combinations pastes. Data are presented as mean ± standard deviation. *
denotes significant differences from all other groups.
Cytocompatibility
NIH3T3 fibroblast cells were seeded at 104 cells/cm2 in 24-well plates and grown in
Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and 100
µg/mL of an antibiotic/antimycotic solution for 24 hours. Approximately 300 mg of dried
material was hydrated using a PBS solution. Hydrated volumes were split into three equal
volumes (~0.5 mL) and injected into cell culture inserts (Falcon, pore size = 8 µm) and placed in
each well. Cells were exposed to pastes eluates for 24 hours and quantified using Cell-Titer Glo
(Promega) assay. Results were expressed as percentage of cells grown on blank tissue culture
plastic. Controls in this study was unmodified chitosan paste (control) and an unmodified
chitosan sponge (sponge).
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FIGURE 20. Preliminary in vitro cytocompatibility results with NIH3T3 fibroblasts for pastes
that elute vancomycin. Data are normalized to cells grown on blank tissue culture plastic and
represented as a mean ± standard deviation. * denotes statistical significance vs. sponge, and #
denotes statistical significance vs. blank.
Conclusion
Combination of control and TMC paste was eliminated by the elution study due to only
eluting for 4 days (Figure 16 and 17). Control would also be eliminated by this criteria, but it
remained as a historical control. PEGDAc was not carried forward to the cytocompatibility study
due to difficulty with handling properties. Both the control and TMC were eliminated in the
cytocompatibility evaluation. Both pastes performed under the benchmark set out by ISO 109935. The combinations of PEGDAc and TMC and PEGDAc and control both eluted for six days
and were cytocompatible according to ISO 10993-5. The combination of PEGDAc and TMC
eluted longer than PEGDAc and control (7 vs. 6 days), but it displays a lower relative viability
(72 vs. 97%) (Figures 17 and 18). However, there was one replicate that performed poorly
compared to the other two, and if this point was excluded, it would be (82% vs. 97%). Further
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research efforts are focused on the combination of PEGDAc and TMC with the possibility of
PEGDAc and control being evaluated in the future.
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APPENDIX C: Refinement of PEGDAc and TMC Combination
Rationale
A combination of PEGDAc and TMC paste was superior to other evaluated pastes, but
other combinations of these two derivatives have not been tested. The 50:50 combination was
above the cytocompatibility benchmark established in ISO 10993-5, but it could be possibly be
improved by adjusting the ratio of PEGDAc to TMC. This is evidenced by the improved
cytocompatibility observed when PEGDAc was mixed with either the control paste or TMC.
Three combinations of PEGDAc and TMC were produced by modifying the weight ratios: 25%
PEGDAc 75% TMC, 50% PEGDAc 50% TMC, 75% PEGDAc 25% TMC. These were
evaluated to see if there was an effect on antimicrobial elution or cytocompatibility.
Antimicrobial elution
Approximately 600 mg of each paste variety was hydrated using a 5 mg/mL combination
solution of vancomycin and amikacin. Combinations were prepared by mixing the appropriate
weight percentages of dried material. Powder was hydrated using a ratio of 4.5 mL solution per
gram of dried powder. Approximately 0.6 mL of hydrated paste (n = 4) was injected into cell
crowns (Scaffdex) with nylon filters (pore size = 41 µm) attached. Each sample was placed in 5
mL of PBS, incubated at 37°C, and sampled daily. Upon sampling, each sample was completely
refreshed with PBS. Vancomycin was detected and quantified using an HPLC system interfaced
with a UV/Vis spectrophotometer. Amikacin was quantified using a previously described method
of pre-column derivatization with an o-phthaldialdehyde reagent and subsequent detection with
an HPLC system using a fluorescence detector.107 Statistical analysis was performed using one
way ANOVA with a SNK post-hoc test to perform comparisons between groups. Differences
were considered significant if p-values were less than 0.05.
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FIGURE 21. Full scale (Days 1-7) preliminary in vitro elution results of vancomycin from
chitosan derivative combinations pastes. Data are presented as mean ± standard deviation. *
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FIGURE 22. Zoomed in (Days 3-7) preliminary in vitro elution results of vancomycin from
chitosan derivative combinations pastes. Data are presented as mean ± standard deviation. *
denotes significant differences from all other groups.
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FIGURE 23. Full scale (Days 1-7) preliminary in vitro elution results of amikacin from chitosan
derivative combinations pastes. Data are presented as mean ± standard deviation. * denotes
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FIGURE 24. Zoomed in (Days 3-7) preliminary in vitro elution results of amikacin from
chitosan derivative combinations pastes. Data are presented as mean ± standard deviation. *
denotes significant differences from all other groups.
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Cytocompatibility
NIH3T3 fibroblast cells were seeded at 104 cells/cm2 in 24-well plates and grown in
Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and 100
µg/mL of an antibiotic/antimycotic solution for 24 hours. Approximately 150 mg of dried
material was hydrated using a PBS solution. Hydrated volumes were split into three equal
volumes (~0.3 mL) and injected into cell culture inserts (Falcon, pore size = 8 µm) and placed in
each well. Cells were exposed to pastes eluates for 24 hours and quantified using Cell-Titer Glo
(Promega) assay. Results were expressed as percentage of cells grown on blank tissue culture
plastic. Statistical analysis was performed using one way ANOVA with a SNK post-hoc test to
perform comparisons between groups. Differences were considered significant if p-values were
less than 0.05.
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FIGURE 25. Preliminary in vitro cytocompatibility results of chitosan derivative combinations
with NIH3T3 fibroblasts. Data are normalized to cells grown on blank tissue culture plastic and
represented as a mean ± standard deviation. * denotes statistical significance from other groups.
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Conclusions
The combination consisting of 75% PEGDAc and 25% TMC was superior to the other
two combinations in eluting vancomycin and amikacin (Figures 19, 20, 21, and 22). This
combination eluted significantly higher concentrations at days 5, 6, and 7 for both antimicrobials.
No significant differences were observed for cytocompatibility with NIH3T3 fibroblasts, but it
appeared that 75% PEGDAc and 25% TMC had a higher relative viability compared to the other
combinations (87% vs. 72% and 76%) (Figure 23). Due to the enhanced elution properties and
cytocompatibility of 75% PEGDAc and 25% TMC, further research efforts are focused on
comparing this combination to previously developed systems.
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APPENDIX D: Ninhydrin Assay
Rationale
TMC and PEGDAc are both produced by derivatizing chitosan at the primary amino
group present on the glucosamine subunit.19,72 The ninhydrin assay is used for the detection of
primary amine groups, and it was determined that this assay could be used as a useful indicator
for reaction success and efficiency.108,109 When the ninhydrin reagent is heated in the presence of
a primary amine groups, a purple reaction product is formed that can be detected using a UV/Vis
spectrophotometer. A ninhydrin test was used to determine the amount of free amino groups
remaining after reaction, which is proportional to the degree of reaction.
Methods and results
Ninhydrin solution was prepared by dissolving 2% (w./v.) ninhydrin reagent in dimethyl
sulfoxide and combined with an acetate buffer (pH = 5.4) to adjust the concentration to 1.5%
(w./v.). Samples (1% w./v.) were dissolved in deionized water and combined with ninhydrin
solution in a 1:1 ratio and heated in a hot water bath at 100°C for 30 minutes. After cooling to
room temperature, reacted solutions were diluted 1:15 using isopropyl alcohol and absorbance at
570 nm was determined using a Biotek Synergy H1 microplate reader. The amount of free amino
groups was determined using a standard curve produced from known chitosan weight
percentages vs. absorbance.
A straight line was obtained when the absorbance of the standard chitosan solutions was
plotted against their concentrations. Absorbance of the PEGDAc solution was not different
compared to the highest concentration of chitosan (3.46 vs. 3.53). Absorbance for DMC and
TMC was similar to the absorbance value for the blanks (0.05 vs. 0.03), and there was no color
change.
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Conclusions
PEGDAc absorbance not being significantly different from the highest concentration of
chitosan is not surprising due to the molar ratio of PEGDA to amino groups present on chitosan,
1:47. If the reaction was performed with 100% efficiency, there would have only been a 2.1%
change in the number of free amino groups. However, the results for TMC were positive for
indication of reaction. The first step in producing TMC is a quantitative dimethylation of the
amino groups. The absorbance of TMC was not significantly different from the blank; this
indicates that no free amino groups were present. Results from this study provide extra support to
the FTIR and NMR analyses that the derivatizations were successfully performed.
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APPENDIX E: Adhesion Testing
Rationale
Complex musculoskeletal trauma wounds have complex geometries that make clinically
used orthopaedic biomaterials less effective.4 An injectable delivery system offers the distinct
advantage of enhanced wound coverage because it can be ejected directly into the wound site. If
the delivery system is not adhesive, it may migrate from the wound site and not deliver
antimicrobials to the affected area. It would be advantageous if an injectable delivery system
could be developed that would adhere to the wound site until a clinician was able to irrigate and
debride the wound site. TMC has been shown to have enhanced mucoadhesivity compared to
unmodified chitosan, but the effects of DQ on mucoadhesivity is still debated.16,78 PEGDAc has
also been shown to have enhanced mucoadhesivity compared to unmodified chitosan and
thiolated chitosan, the most adhesive class of chitosan derivatives.16,19 Therefore, a combination
of 75% PEGDAc and 25% TMC was evaluated to determine if mucoadhesivity was enhanced
compared to an unmodified chitosan delivery system.
Methods and results
Fresh muscle tissue was harvested from the hind legs of New Zealand White rabbits and
used as a model tissue for muscle tissue in a complex musculoskeletal injury. Tissues were
coated in approximately 4 mL of fetal bovine serum (FBS) to simulate surface proteins. Dried
powder was hydrated using 4.5 mL of PBS per gram of dried powder, and approximately ~0.9
mL of paste (n = 3) was ejected on the tissue. Paste was allowed to sit for 1 minute to visually
assess adhesion to the muscle tissue. After assessing initial adhesion, 10 mL of PBS was applied
to the paste to simulate irrigation used in the management of complex musculoskeletal injuries.
This step was repeated three times, or until the paste was removed from the tissue.
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Unmodified control pastes were unable to maintain their initial position, and gravity
immediately began to dislodge them (Figure 25a). Addition of PBS facilitated the removal of
paste from the tissue. The combination of PEGDAc and TMC immediately adhered to the tissue
and showed no evidence of movement after 1 minute (Figure 25b). Addition of PBS directly to
the paste completely removed it from the tissue, and adding PBS to the tissue above the paste
produced swelling and gradual removal (Figure 25c).

FIGURE 26. Pastes ejected onto representative tissue. (a) Image of control paste. (b) Image of
combination paste prior to PBS wash. (c) Previous image immediately after PBS wash
Conclusions
Combination paste successfully adhered to representative muscle tissue prior to simulated
irrigation with PBS. This is advantageous over the control paste that had difficulty adhering to
the simulated wound site and was unable to be washed away. Combination paste could be
applied immediately after injury occurs, and it would remain in place until a clinician was ready
to irrigate and debride the wound site. Then, more combination paste could be applied to the
clean wound site for further infection prevention, and it could be removed by additional
irrigation or degradation within the body depending if the wound was left open or closed. An
interesting observation was made when the hydration ratio was increased to 7.0 mL from 4.5 mL
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per gram of dry paste. The resulting paste was easier to inject, held more antimicrobial solution,
and was more resilient to irrigation with PBS (Figures 26a and 26b).

FIGURE 27. Pastes with different hydration ratios ejected onto representative tissue. (a) 4.5 mL
on left and 7.0 mL on right (b) Pastes after irrigation with PBS
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